MGF (Mechano Growth Factor): An IGF-1 Splice Variant for Muscle Repair Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to MGF (mechano growth factor). MGF is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Your skeletal muscle already produces a signal for repair when it is mechanically overloaded. The signal is not a drug. It is a short peptide generated by an alternative splice of the same gene that produces IGF-1. In laboratory and animal models, this peptide activates the satellite cells (muscle stem cells) responsible for repair and regeneration. In aging muscle, its production appears to be blunted. What that observation means clinically — and whether a synthetic version can replicate or augment it — is the central unresolved question in the MGF research literature.

Here is what mechano growth factor is, how its biology was characterized, where the evidence stands as of April 2026, and why the gap between preclinical promise and clinical evidence remains wide.

Key Takeaways

• Regulatory Status: As of April 2026, MGF is not FDA-approved for any indication. It is classified as a research-use-only compound and is not legally available by prescription in the United States.
• Research Stage: Preclinical (animal models and in vitro); limited and non-definitive human data; no completed human efficacy RCTs.
• Availability: Not available through Superpower. MGF and PEG-MGF are sold through online research chemical vendors, but these products are not regulated by the FDA and have not been evaluated for safety, identity, or purity in humans.
• Compound reference: PubChem CID 175675731 — MGF E-peptide
• How it works: MGF is a 24-amino-acid C-terminal E-peptide fragment generated when the IGF-1 gene is alternatively spliced under mechanical or hypoxic stress, activating satellite cells for muscle repair.
• What the research shows: Rodent and in vitro studies indicate satellite cell activation and cardioprotective effects; one independent laboratory found no myoblast effect, highlighting replication gaps.

What Is MGF?

Mechano growth factor (MGF) is the common name for the E-peptide fragment produced by a specific splicing of the IGF-1 gene. The IGF-1 gene can generate multiple protein isoforms depending on which exons are combined. In humans, the two primary muscle-relevant isoforms are IGF-1Ea (the predominant systemic form, also called liver-type IGF-1) and IGF-1Ec (the locally expressed mechano-responsive form, also called MGF). In rodents, the equivalent mechano-responsive isoform is called IGF-1Eb. The nomenclature varies by species and has been a source of confusion in the literature.

The IGF-1 gene produces a precursor protein. Depending on the splice variant, this precursor contains a different C-terminal extension called the E-domain. When IGF-1Ec is cleaved, the resulting 24-amino acid E-domain peptide — the MGF E-peptide — appears to have biological activity independent of the mature IGF-1 portion. The mature IGF-1 domain, once released, signals through the IGF-1 receptor to drive cell differentiation. The E-peptide, in contrast, appears to act upstream by driving myoblast (muscle progenitor) proliferation before differentiation is initiated. This functional separation between the E-peptide and mature IGF-1 portions was characterized by Yang and Goldspink in a 2002 paper in FEBS Letters, which remains one of the foundational mechanistic references in this field. Philippou, Maridaki, Halapas, and Koutsilieris, writing in In Vivo in 2007, reviewed the broader IGF-1 system in skeletal muscle physiology and placed the IGF-1Ea, IGF-1Eb, and IGF-1Ec (MGF) isoforms within a single signaling framework, helping clarify how the same gene can generate systemic and locally induced anabolic signals. Philippou, Papageorgiou, Armakolas, Christopoulos, and Koutsilieris followed up in Growth Hormone and IGF Research in 2010 with a more focused review of IGF-1Ec expression, regulation, and biological function across tissues, documenting that the mechano-responsive isoform is expressed in contexts beyond skeletal muscle.

The Goldspink Lab and the Origins of the MGF Concept

Identification of the mechano-responsive splice variant

The experimental basis for MGF was established by Geoffrey Goldspink and colleagues at University College London in a series of papers beginning in the late 1990s. McKoy, Ashley, Yang, and colleagues, publishing in the Journal of Physiology in 1999, reported that rabbit skeletal muscle subjected to stretch plus electrical stimulation produced a distinct IGF-1 isoform — the MGF/IGF-1Ec form — that differed from the liver-type IGF-1Ea, with electrical stimulation alone producing no significant IGF-1 change. This mechanically induced splice variant was the experimental basis for the "mechano growth factor" name. The observation introduced the idea that skeletal muscle produces a local, context-specific IGF-1 isoform in response to mechanical loading rather than relying solely on circulating growth hormone and liver-derived IGF-1.

Satellite cell activation and muscle stem cell biology

The key mechanistic proposal from the Goldspink group was that the MGF E-peptide specifically activates satellite cells — the quiescent muscle stem cells responsible for repairing damaged muscle fibers. Hill and Goldspink in a 2003 Journal of Physiology paper, reported that IGF-1 splicing in rodent muscle was associated with satellite cell activation following local tissue damage, identifying a mechanistic link between the splice event and the cells responsible for muscle regeneration. This framing — MGF as a satellite cell activator, mature IGF-1 as a differentiation driver — established the two-signal model that Goldspink's group would develop over the following decade.

The two-signal model: proliferation vs. differentiation

The most-cited mechanistic paper from the Goldspink group is the 2002 Yang and Goldspink FEBS Letters study, which tested the E-peptide and mature IGF-1 portions in separate experiments on cultured myoblasts. The E-peptide increased myoblast proliferation but not differentiation. Mature IGF-1 increased differentiation but not proliferation to the same degree. This functional separation was presented as evidence that the two cleavage products of IGF-1Ec act sequentially: the MGF E-peptide first expands the pool of muscle progenitor cells, then mature IGF-1 drives those cells to fuse and form new muscle fibers. This model has been widely cited but, as discussed below, has not been independently confirmed in all experimental systems.

MGF and Aging Muscle

Blunted MGF response in older adults

One of the clinically relevant observations from the Goldspink group was that aging muscle appears to lose the ability to upregulate MGF in response to mechanical overload. Owino, Yang, and Goldspink, publishing in FEBS Letters in 2001, reported age-related loss of skeletal muscle function alongside an inability to express MGF in response to mechanical overload — connecting the MGF response to sarcopenia biology. This was among the first papers to suggest that declining MGF expression could contribute to the progressive loss of muscle mass and regenerative capacity seen with aging. Goldspink returned to this theme in a 2006 review in the International Journal of Biochemistry and Cell Biology, synthesizing evidence on how impaired IGF-1 gene splicing and the resulting drop in MGF expression track with muscle wasting across disuse, denervation, and age-related contexts. Velloso and Harridge, writing in the Scandinavian Journal of Medicine and Science in Sports in 2010, reviewed the broader IGF-1 E-peptide literature with specific attention to ageing skeletal muscle, concluding that splice-variant biology is a plausible contributor to anabolic resistance in older adults even where the direct therapeutic implications remain unresolved.

Human data on this question is limited but directionally consistent. Hameed, Orrell, Cobbold, Goldspink, and Harridge, publishing in the Journal of Physiology in 2003, analyzed IGF-1 splice variant expression in vastus lateralis biopsies from young (25–36 years) and elderly (70–82 years) men after a single bout of high-resistance exercise. This was one of the earliest human datasets showing age-related blunting of the MGF response: MGF mRNA rose significantly in younger subjects but did not rise in older subjects, while IGF-IEa was unchanged by exercise in either group — suggesting an age-related desensitization to mechanical loading at the level of IGF-1 gene splicing. A later study by Moore, McKay, Tarnopolsky, and Parise, published in the European Journal of Applied Physiology in 2018, compared seven younger men (22 ± 2 years) and seven older men (70 ± 2 years) after a single bout of unilateral resistance exercise, with muscle biopsies taken up to 48 hours post-exercise. Satellite-cell content increased by 24 hours in young subjects only (interaction p < 0.05), while older subjects showed delayed IGF-1Ec mRNA increases at 24 and 48 hours (interaction p < 0.05) — human observational evidence consistent with the age-related decline hypothesis, though the very small per-group sample (n = 7 each) limits the strength of this finding and the study authors interpret the compensatory IGF-1Ec response as a possible countermeasure to anabolic resistance rather than a pure deficit. These are observational findings; neither study was designed to test whether exogenous MGF supplementation can reverse this decline in humans.

MGF framed against myostatin

Goldspink has also framed MGF as an anabolic counterpart to myostatin — the negative regulator of muscle growth. In a 2007 paper in Rejuvenation Research, he discussed loss of muscle strength during aging at the gene expression level, positioning reduced MGF alongside elevated myostatin as part of the anabolic-catabolic imbalance that drives sarcopenia. This framing contributed to interest in MGF as a potential sarcopenia intervention, though no human interventional data on this hypothesis exists.

PEG-MGF: The Synthetic Research Version

Why native MGF has a very short half-life

Native MGF E-peptide is rapidly degraded in serum. The 24-amino-acid sequence is susceptible to proteolysis, giving it an estimated half-life of minutes in biological fluids. This rapid clearance makes native MGF impractical as an injectable research compound for studying sustained biological effects in vivo. For this reason, researchers and the research chemical market have focused primarily on PEG-MGF: a version where polyethylene glycol (PEG) is attached to the peptide, typically at the N-terminal tyrosine residue. Pegylation sterically protects the peptide from proteolytic enzymes and substantially extends its circulating half-life from minutes to potentially days, depending on the PEG moiety size and attachment site.

Research use of PEG-MGF

PEG-MGF is the form most commonly referenced in animal studies and sold through online research chemical vendors. Because PEG-MGF's extended half-life enables sustained receptor exposure after a single injection in rodent models, most of the published animal data on systemic MGF effects uses PEG-MGF rather than native MGF. It is important to note that PEG-MGF is a synthetic construct that does not exist endogenously — the endogenous E-peptide is the native, rapidly cleared fragment. PEGylated analogs may have different receptor binding kinetics, off-target interactions, and tissue distribution profiles compared to the short-lived native peptide. No comparative pharmacokinetic or pharmacodynamic data in humans exists for either form.

What the Preclinical Evidence Actually Shows

Satellite cell and muscle regeneration data

The majority of positive MGF data comes from rodent and in vitro models. Matheny, Nindl, and Adamo published a balanced minireview in Endocrinology in 2010 that described MGF as a putative product of IGF-1 gene expression involved in tissue repair and regeneration, while explicitly flagging the evidence gaps that persist around receptor identification, pharmacokinetics, and clinical translation. That framing is worth holding in mind when reading the positive findings below. Ascenzi, Filigheddu, Peluso, Sbraccia, and Marcelli reviewed the broader interplay between myogenic regulatory factors and IGF pathways, including IGF-1Ec/MGF, in Cellular and Molecular Life Sciences in 2013, situating MGF within the network of transcription factors that coordinate skeletal muscle hypertrophy and regeneration. Kandalla, Goldspink, Butler-Browne, and Mouly, publishing in Mechanisms of Ageing and Development in 2011, reported in an in vitro study of primary human muscle satellite cells from neonatal, young-adult, and old-adult donors that synthetic MGF E-peptide exposure significantly increased proliferative lifespan and delayed replicative senescence in neonatal and young-adult cells, with diminished responsiveness in old-adult cells — providing direct human myoblast mechanistic data while itself documenting an age-related decline in responsiveness. Per-group donor numbers and exact effect sizes are not reported in the abstract, and cell-culture conditions differ substantially from in vivo physiology; these limitations warrant caution in extrapolating to clinical outcomes. Matheny, Merritt, Zannikos, Farrar, and Adamo, publishing in Molecular and Cellular Endocrinology in 2015, added a further mechanistic layer by showing that subfragments of myofibrillar proteins can themselves induce IGF-1 splice forms, including MGF, suggesting that the mechano-responsive splicing program may be triggered in part by proteolytic fragments released during muscle damage.

In rodent models, Pelosi and colleagues, publishing in Frontiers in Physiology in 2018, reported that MGF overexpression in mice modulated inflammatory cytokine expression and macrophage resolution after skeletal muscle injury — suggesting an interaction with the post-injury inflammatory environment. Song and colleagues, publishing in Frontiers in Physiology in 2019, reported in a rodent model that MGF injection partly ameliorated impaired skeletal muscle regeneration caused by macrophage depletion, further implicating MGF in the immune-mediated phase of muscle repair. These mechanistic findings in rodents are consistent with a role in muscle regeneration biology but cannot be extrapolated to confirm efficacy in humans.

The critical negative finding

Not all research supports the Goldspink-lab mechanistic model. Fornaro, Hinken, and colleagues, publishing in the American Journal of Physiology - Endocrinology and Metabolism in 2014, tested synthetic MGF E-peptide at concentrations up to 500 ng/mL in C2C12 myoblasts, primary human skeletal muscle myoblasts, and primary mouse skeletal muscle stem cells, using methods designed to independently replicate the original Goldspink-lab assays. Their finding was negative: the MGF E-peptide failed to increase proliferation, failed to inhibit differentiation into myotubes, and had no apparent effect on primary muscle stem cell activation — whereas mature IGF-1 and full-length IGF-1Eb produced robust proliferative responses in the same cells. This is a significant result. It was published in a high-quality journal, used primary human cells, and directly contradicts the central mechanistic claim of the Goldspink-lab papers. The discrepancy has not been fully resolved in the published literature and represents a replication gap that prevents strong conclusions about the MGF E-peptide's direct cellular mechanism.

Cardiac and neural preclinical research

MGF research extends beyond skeletal muscle. Carpenter, Quesada, and colleagues, publishing in Heart, Lung and Circulation in 2008, reported that intramyocardial MGF E-domain peptide at 200 nM administered in a sheep model of induced acute myocardial infarction produced approximately 35% less compromised cardiac muscle at 8 days post-MI compared with controls, with improved post-infarction cardiac function and absent cleaved caspase-3 immunostaining in treated hearts — making it one of the key preclinical cardiac papers in this area, though the abstract does not report animal numbers or formal p-values and the finding remains a single-laboratory preclinical result in a non-human species. Stavropoulou and colleagues, publishing in Molecular Medicine in 2009, examined IGF-1 expression in infarcted rat myocardium and reported MGF E-peptide actions in rat cardiomyocytes in vitro. More recently, Doroudian and colleagues, publishing in Biomedical Microdevices in 2014, reported that sustained delivery of MGF peptide from microrods attracted stem cells and reduced cardiomyocyte apoptosis in a translational cardiac delivery model. In the neural domain, Tang and colleagues, publishing in Molecular Brain in 2017, used constitutive and inducible MGF-overexpressing transgenic mouse lines (n = 4 per group for hippocampal analysis, 4–8 per group for olfactory behaviour) and reported that MGF overexpression significantly increased BrdU-positive proliferating cells in the hippocampal dentate gyrus and olfactory bulb, with neurosphere formation from MGF-overexpressing neural stem cells significantly increased in both number and size (p < 0.01) — a preclinical genetic-overexpression signal in mice, not exogenous peptide administration, and not demonstrated in humans. All of these findings are in animals; none has been tested in human clinical trials.

Human Evidence: What Exists and What It Shows

As of April 2026, no completed randomized controlled trials of exogenous MGF or PEG-MGF administration have been published in peer-reviewed journals. The human data that exists falls into two categories: observational studies measuring endogenous MGF expression after exercise, and one interventional study examining the effect of recombinant human growth hormone (rhGH) on IGF-1 splice variant expression.

Hameed, Lange, Andersen, Schjerling, Kjaer, Harridge, and Goldspink, publishing in the Journal of Physiology in 2004, examined the effects of rhGH combined with resistance training on IGF-1 mRNA isoforms (including MGF) in elderly men. This study measured endogenous splice variant expression as a downstream effect of GH administration, not the direct administration of MGF. Aperghis, Velloso, Hameed, and colleagues, publishing in Growth Hormone and IGF Research in 2009, provided rare human interventional splice-variant data by measuring IGF-1 splice variants in healthy young males receiving rhGH — again as an indirect window into MGF biology rather than a direct test of exogenous MGF.

The absence of human RCTs means that claims about MGF's clinical efficacy — for muscle building, recovery, sarcopenia reversal, or any other application — are not supported by the kind of controlled evidence that would be required for FDA review. The gap between the preclinical literature and clinical translation is substantial and, as of the current publication date, unresolved.

Regulatory Status and WADA Classification

FDA status

As of April 2026, MGF (mechano growth factor) is not FDA-approved for any indication. It has not been evaluated by the FDA for safety, efficacy, or quality in humans. MGF is not available by prescription in the United States. Products sold online as MGF or PEG-MGF are research chemical products and are not subject to FDA quality standards or oversight. Independent testing of such products has documented contamination, incorrect peptide sequences, and impurities. Esposito and colleagues, publishing in Rapid Communications in Mass Spectrometry in 2012, characterized a C-terminal amidated MGF analogue found in black-market products, illustrating that commercial MGF preparations may differ structurally from the sequence used in published research.

WADA classification

MGF has been of interest to anti-doping authorities because its proposed anabolic mechanism in muscle has led to its use in competitive sport. As of the 2026 WADA Prohibited List, MGF falls within the Prohibited List category for growth factors and related substances. Goldspink, writing in Current Opinion in Pharmacology in 2008, directly addressed MGF in the context of doping, describing both the scientific basis for its potential misuse and the analytical challenges of detection. Barroso, Schamasch, and Rabin in a 2009 review in Growth Hormone and IGF Research written from within WADA, situated MGF detection within the broader GH abuse framework, outlining the isoform differential immunoassay and biomarker-based approaches used in WADA-accredited laboratories to identify manipulation of the GH-IGF-1 axis in tested athletes. Thevis, Thomas, Geyer, and Schänzer, publishing in Growth Hormone and IGF Research in 2014, characterized a biotechnologically produced full-length MGF preparation (monoisotopic molecular mass 12,264.9 Da, closely related to IGF-1Ec) and developed a mass-spectrometric method with a detection limit of 0.25 ng/mL specifically for doping-control use. More recently, Cox, Knussmann, Moore, and Eichner, publishing in Drug Testing and Analysis in 2022, reported on detection of insulin analogues and large peptides over 2 kDa (including MGF-class peptides) in urine with detection limits of 5–25 pg/mL, representing contemporary WADA analytical methodology. Athletes subject to anti-doping controls should treat MGF as a prohibited substance regardless of its availability status.

A note on IGF-1Ec and tumor biology

A separate area of research examines IGF-1Ec expression in tumor biology. Kasprzak and Szaflarski, publishing in the International Journal of Molecular Sciences in 2020, reviewed alternatively spliced IGF-1 mRNA isoforms across human tissues and tumors, noting that IGF-1Ec expression has been detected in various cancer contexts. The significance of this for the safety of exogenous MGF administration in humans is unknown, but it constitutes a theoretical concern warranting attention in any future clinical investigation — particularly for individuals with personal or family history of IGF-pathway-related cancers.

Which Biomarkers Are Relevant if You Are Exploring Growth Factor Biology?

MGF is not available through Superpower and has no established clinical application. However, understanding the broader growth hormone and IGF-1 axis is relevant for anyone interested in the biology MGF research addresses — including muscle function, sarcopenia risk, and age-related decline in anabolic signaling. The following biomarkers are directly relevant to this axis.

• IGF-1 (Insulin-Like Growth Factor 1): The primary systemic marker of growth hormone axis activity. IGF-1 is the downstream signal through which growth hormone drives anabolic processes in muscle, bone, and other tissues. Baseline IGF-1 provides context for understanding where a person sits on the anabolic signaling spectrum and whether age-related decline in GH pulsatility is reflected in blood levels. Reference ranges are age-adjusted; declining levels with age are a normal but potentially modifiable finding.
• Growth hormone (GH): Measured as a fasting or stimulated level. Because GH is secreted in pulses, a single measurement has limited diagnostic value without context, but IGF-1 provides an integrated window into GH axis function across the preceding hours to days.
• Fasting glucose and insulin: IGF-1 shares structural homology with insulin and signals through a related receptor family. Chronically elevated insulin is associated with downregulation of GH secretion through somatostatin pathways. Assessing insulin sensitivity via fasting glucose and insulin provides metabolic context for interpreting IGF-1 levels and for understanding the anabolic environment in which muscle repair occurs.
• Testosterone (men) and estradiol (women): Sex hormones and the GH-IGF-1 axis interact bidirectionally. Testosterone supports IGF-1 production; IGF-1 supports testicular function. In women, estradiol modulates hepatic IGF-1 production. Assessing sex hormone status alongside IGF-1 provides a more complete picture of the anabolic environment.
• Complete blood count (CBC) and comprehensive metabolic panel: Provide safety baseline data relevant to growth factor biology, including liver function (IGF-1 is primarily produced in the liver) and hematologic status.

Safety: What Is Not Known

The absence of completed human clinical trials means that the safety profile of exogenous MGF or PEG-MGF in humans is essentially unknown. The following concerns are based on proposed mechanisms, related compound data, and theoretical considerations rather than documented human adverse events.

Known unknowns:

• No human pharmacokinetic data for exogenous MGF or PEG-MGF: dosing, distribution, metabolism, and elimination in humans have not been characterized
• No human safety data: adverse event frequency and severity are unknown
• No long-term exposure data in any species outside short-duration rodent experiments
• PEGylation: the long-term accumulation and clearance of the PEG moiety in human tissue is not characterized for this specific compound

Theoretical concerns based on mechanism:

• IGF-1 pathway activation is associated with cell proliferation; in individuals with pre-existing neoplastic conditions or high cancer risk, growth factor activity is a theoretical concern
• IGF-1Ec expression has been documented in tumor contexts, as noted by Kasprzak and Szaflarski (2020); the relevance of exogenous E-peptide for cancer risk is unknown
• Cardiac effects: the preclinical cardiac papers suggest MGF has biological activity in myocardial tissue; cardiac effects of exogenous administration in humans with pre-existing heart conditions have not been studied
• Immune response: exogenous peptides can trigger immune reactions, including antibody formation; no immunogenicity data for MGF in humans exists

Unregulated product risks:

• Products sold online as MGF or PEG-MGF are not subject to FDA oversight, Good Manufacturing Practice standards, or quality testing requirements
• As documented by Esposito and colleagues (2012), black-market MGF preparations may contain structurally different analogues, contaminants, or incorrect concentrations
• Injection of unsterile or contaminated peptide preparations carries direct infection risk

Who Should Not Use MGF

Because MGF is not FDA-approved and has no established clinical application, there is no formal contraindication list derived from approved prescribing information. Based on the compound's proposed mechanisms and the theoretical concerns above, the following groups face elevated theoretical risk.

• Individuals with active or personal history of any cancer, particularly those involving IGF-1 pathway signaling (breast, prostate, colorectal), given growth factor activity and documented IGF-1Ec expression in tumor contexts
• Individuals with known or suspected acromegaly or other conditions involving excess IGF-1 pathway activity
• Individuals with active cardiac conditions, given preclinical evidence of cardiac bioactivity and the absence of human cardiac safety data
• Pregnant or breastfeeding individuals: safety during pregnancy and lactation has not been studied
• Individuals on immunosuppressive therapy or with active autoimmune conditions: immune interactions with exogenous peptides are unpredictable without data
• Athletes subject to anti-doping controls: MGF is prohibited under the WADA Prohibited List

This is not a complete list. The absence of human safety data means that risk cannot be fully characterized. Anyone considering MGF for any purpose should consult a qualified healthcare provider before proceeding.

Is MGF Legal?

As of April 2026, MGF is not FDA-approved for any indication. It is not available by prescription in the United States and is not eligible for compounding under standard 503A or 503B pathways for human use. Products sold online as MGF or PEG-MGF are marketed as research chemicals and are labeled for laboratory use only — a designation that does not authorize human use.

The legal status of purchasing such compounds for personal use varies by jurisdiction and is outside the scope of this article. What is clear is that no FDA-regulated pathway currently exists for an individual to obtain MGF or PEG-MGF as a legitimate prescription or OTC product for human use in the United States. For athletes, the WADA prohibition applies regardless of local legal availability. The compound reference for the MGF E-peptide is PubChem CID 175675731.

Understanding Your Growth Factor Biology

The research interest in MGF reflects a genuine biological question: why does skeletal muscle's regenerative capacity decline with age, and can that decline be reversed? The IGF-1 splice variant data from the Goldspink group and from independent exercise physiology research points toward the GH-IGF-1 axis as a central regulator of this capacity. Whatever the eventual fate of MGF as a clinical compound, the underlying biology — satellite cell activation, IGF-1 signaling, and the interplay between mechanical loading and anabolic gene expression — is well established.

For individuals interested in where their anabolic biology actually stands, the most direct path is objective measurement. IGF-1, fasting insulin, fasting glucose, and sex hormone levels collectively describe the anabolic environment in which muscle repair occurs. These are measurable today, with established reference ranges, and their results carry direct clinical meaning that a provider can act on. This is the approach that Superpower was built around: that understanding your own biology through objective data, as articulated in the Superpower manifesto, is the foundation of any rational health decision. Understanding what your markers show comes before any decision about what to do next.

IMPORTANT SAFETY INFORMATION

MGF (mechano growth factor, also known as IGF-1Ec) and its pegylated form (PEG-MGF) are not FDA-approved for any indication. No NDA or IND has been filed, and no DailyMed prescribing information exists. MGF is not eligible for compounding under 503A or 503B pathways for human use. Products sold online as MGF or PEG-MGF are labeled for laboratory "research use only"; this designation does not authorize human use. Superpower is a technology platform; Superpower does not prescribe, sell, compound, or facilitate access to MGF or PEG-MGF.

Do not use MGF if you: have an active or suspected malignancy (IGF-1 signaling is implicated in tumor proliferation pathways); have a personal or family history of hormone-sensitive cancers; are pregnant, may become pregnant, or are breastfeeding; are a minor; have diabetes or significant insulin resistance (IGF-1 pathway modulation may affect glucose handling); or have known hypersensitivity to any peptide formulation.

Warnings: Products labeled as MGF or PEG-MGF sold through online research-chemical vendors have not been evaluated for identity, potency, sterility, or contamination; independent testing of unregulated peptide products has documented contamination with endotoxin, heavy metals, and misidentified compounds. No published human Phase 1 safety trial has been completed for MGF or PEG-MGF. The theoretical risk of IGF-1 receptor signaling includes acromegaly-like effects at supraphysiologic doses, hypoglycemia, and theoretical tumor-growth concerns; none of these have been characterized in human controlled trials.

Common side effects: Not established. No controlled human trial data exist. Anecdotal reports from unregulated use cannot substitute for safety data.

WADA status: MGF is prohibited at all times under the World Anti-Doping Agency 2026 Prohibited List, category S2 (peptide hormones, growth factors, and related substances). Athletes subject to anti-doping controls should not use MGF under any circumstances; detection is possible on standard blood and urine panels.

Long-term data limitations: No completed human clinical efficacy or safety trials exist for MGF or PEG-MGF as of April 2026. The preclinical literature consists primarily of animal models and in-vitro experiments; translation to human physiology has not been established.

Compound reference: PubChem CID 175675731 (MGF E-peptide). No FDA-approved prescribing information exists.

Additional Questions

What are the risks of using MGF from online vendors?

Products sold online as MGF or PEG-MGF are research chemicals not regulated by the FDA. They are not evaluated for identity, potency, purity, or sterility in humans. Independent analytical work has documented structurally modified analogues and contaminants in commercial MGF preparations. Injection of unverified peptide compounds carries risks of infection, immune response, and exposure to unknown substances. The safety profile of exogenous MGF or PEG-MGF in humans is essentially unknown because no human clinical trials have been completed, and the absence of adverse event data is not the same as established safety.

If I am interested in muscle regeneration biology, what should I test?

The most relevant biomarker for the biology MGF research addresses is IGF-1, which reflects overall growth hormone axis activity and provides an age-adjusted benchmark for anabolic signaling capacity. Fasting glucose and fasting insulin describe the metabolic environment that modulates GH secretion. Testosterone in men and estradiol in women provide context for the anabolic hormonal environment. These markers have established reference ranges, are measurable through standard blood testing, and provide a factual baseline that a provider can use to guide evidence-based decisions about muscle health and recovery support.